RNAZ
Transcode Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.70
+0.00%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -74.3%
- EBIT
- —
- EPS
- +33.9%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- -78.7%
- Net income
- —
- EPS
- -11.6%
- Free cash flow
- -46.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026